Doximity reported Q2 revenue of $174.5 million, up 4% year-on-year, raised FY27 revenue guidance to $678 to $683 million, and said AI Search became an eight-figure bookings product, with 16 of the top 20 pharma companies purchasing programs.
DOCS · Doximity, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Doximity reported revenue of $174.5 million for the three months ended September 30, 2026, up 4% from $168.5 million. Net income fell to $34.7 million from $62.1 million, while gross margin decreased 5 percentage points due to increased costs supporting AI initiatives.
Doximity reported fiscal 2027 second-quarter revenue of $174.5 million, up 4% year-over-year, while net income fell to $34.7 million. It expects fiscal 2027 revenue of $678 million to $683 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY27 earnings call · Nov 5, 2026TL;DR. Doximity raised FY27 revenue guidance, reported broad AI Search adoption and strong workflow growth, improved AI infrastructure efficiency, maintained substantial liquidity and cash generation, and received positive early reaction to its UpToDate partnership. The quarter nevertheless showed lower net income, EPS and adjusted EBITDA, nearly flat free cash flow, higher stock compensation and tax rates, trough-level net revenue retention, and a risk of delayed AI Search revenue.
- + FY27 revenue guidance was raised to $678 million-$683 million, implying 6% growth at the midpoint. new
- + Workflow usage reached more than half of U.S. prescribers and grew 34% year over year. new
- + Cost of revenue grew at less than half the rate of overall prompt volume in Q2, indicating improved AI infrastructure efficiency. new
- − Adjusted EBITDA fell 12% year over year and margin contracted to 50.9% from 59.8%. new
- − Free cash flow was nearly flat year over year and operating cash flow declined 1%.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $74.8M | fiscal 2027 first quarter | — |
| Adjusted EBITDA margin non-GAAP | 47.7% | fiscal 2027 first quarter | — |
| Free cash flow non-GAAP | $39.6M | fiscal 2027 first quarter | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities 41.99M
-62K Purchases of property and equipment
-2.32M Internal-use software development costs
= Free cash flow 39.6M
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DOCS
this stock
Doximity, Inc.
|
$5.95B | -24.7% | +13.1% | 47.0 | 3.9% |
|
VEEV
Veeva Systems Inc
|
$48.82B | +35.1% | +28.1% | 49.4 | 2.4% |
|
PMDIY
Pro Medicus Ltd.
|
$14.81B | -14.6% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$14.17B | +90.1% | +28.2% | 38.7 | 5.8% |
|
TEM
Tempus AI, Inc.
|
$13.06B | +21.3% | +83.4% | — | 13.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 5, 2026
- This year
- 13
Doximity reported fiscal 2027 second-quarter revenue of $174.5 million, up 4% year-over-year, while net income fell to $34.7 million. It expects fiscal 2027 revenue of $678 million to $683 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DOCS | +2.6% | +7.7% | +70.8% | +1.8% | -24.7% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | 0.0% | +8.8% | +70.3% | +2.0% | -35.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.